Warning: This security is no longer trading.
Gilead Completes Acquisition of Forty Seven, Inc.
Forty Seven, Inc. (FTSV): Price and Financial Metrics
FTSV Price/Volume Stats
| Current price | $95.51 | 52-week high | $95.52 |
| Prev. close | $95.46 | 52-week low | $5.53 |
| Day low | $95.46 | Volume | 693,900 |
| Day high | $95.52 | Avg. volume | 1,606,836 |
| 50-day MA | $70.16 | Dividend yield | N/A |
| 200-day MA | $28.75 | Market Cap | 4.60B |
FTSV Stock Price Chart Interactive Chart >
Forty Seven, Inc. (FTSV) Company Bio
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was founded in 2014 and is based in Menlo Park, California.
FTSV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 718.42% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 150.45% |
Loading social stream, please wait...